본문 바로가기
KERD
논문KCI 등재

Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

주제분류의학일반

초록

Purpose: Patients with gastroesophageal reflux disease without esophagitis show varying responses to proton pump inhibitors(PPIs). The aim of this study was to objectively evaluate the effect of a new PPI, ilaprazole, on patients with heartburn but withoutreflux esophagitis. Materials and Methods: This prospective study was performed on 20 patients with heartburn but without reflux esophagitis. Allpatients underwent upper endoscopy and 24-hr combined multichannel intraluminal impedance and pH esophageal monitoring(MII-pH). They were then treated with ilaprazole (20 mg) once daily for 4 weeks. The GerdQ questionnaire, histologic findings,and inflammatory biomarkers were used for assessment before and after ilaprazole. Results: Among the 20 patients, 13 (65%) showed GerdQ score ≥8. Based on MII-pH results, patients were classified as true nonerosivereflux disease (n=2), hypersensitive esophagus (n=10), and functional heartburn (n=8). After treatment, patients showeda statistically significant improvement in GerdQ score (p<0.001). Among histopathologic findings, basal cell hyperplasia, papillaryelongation, and infiltration of intraepithelial T lymphocytes improved significantly (p=0.008, p=0.021, and p=0.008; respectively). Expression of TNF-α, IL-8, TRPV1, and MCP-1 decreased marginally after treatment (p=0.049, p=0.046, p=0.045, andp=0.042; respectively). Conclusion: Daily ilaprazole (20 mg) is efficacious in improving symptom scores, histopathologic findings, and inflammatorybiomarkers in patients with heartburn but no reflux esophagitis.

Abstract

Purpose: Patients with gastroesophageal reflux disease without esophagitis show varying responses to proton pump inhibitors(PPIs). The aim of this study was to objectively evaluate the effect of a new PPI, ilaprazole, on patients with heartburn but withoutreflux esophagitis. Materials and Methods: This prospective study was performed on 20 patients with heartburn but without reflux esophagitis. Allpatients underwent upper endoscopy and 24-hr combined multichannel intraluminal impedance and pH esophageal monitoring(MII-pH). They were then treated with ilaprazole (20 mg) once daily for 4 weeks. The GerdQ questionnaire, histologic findings,and inflammatory biomarkers were used for assessment before and after ilaprazole. Results: Among the 20 patients, 13 (65%) showed GerdQ score ≥8. Based on MII-pH results, patients were classified as true nonerosivereflux disease (n=2), hypersensitive esophagus (n=10), and functional heartburn (n=8). After treatment, patients showeda statistically significant improvement in GerdQ score (p<0.001). Among histopathologic findings, basal cell hyperplasia, papillaryelongation, and infiltration of intraepithelial T lymphocytes improved significantly (p=0.008, p=0.021, and p=0.008; respectively). Expression of TNF-α, IL-8, TRPV1, and MCP-1 decreased marginally after treatment (p=0.049, p=0.046, p=0.045, andp=0.042; respectively). Conclusion: Daily ilaprazole (20 mg) is efficacious in improving symptom scores, histopathologic findings, and inflammatorybiomarkers in patients with heartburn but no reflux esophagitis.

참고문헌 (34)

  1. Dent J, "Epidemiology of gastro-oesophageal reflux disease: a systematic review", Gut, 54, pp.710~717 (2005)[DOI]
  2. Dent J, "Microscopic esophageal mucosal injury in nonerosive reflux disease", Clin Gastroenterol Hepatol, 5, pp.4~16 (2007)[DOI]
  3. Savarino E, "NERD: an umbrella term including heterogeneous subpopulations", Nat Rev Gastroenterol Hepatol, 10, pp.371~380 (2013)[DOI]
  4. Savarino E, "The role of nonacid reflux in NERD: lessons learned from impedance- pH monitoring in 150 patients off therapy", Am J Gastroenterol, 103, pp.2685~2693 (2008)[DOI]
  5. Dean BB, "Effectiveness of proton pump inhibitors in nonerosive reflux disease", Clin Gastroenterol Hepatol, 2, pp.656~664 (2004)[DOI]
  6. Ji XQ, "Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis", World J Gastroenterol, 20, pp.5119~5123 (2014)[DOI]
  7. Periclou AP, "A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease", Clin Pharmacol Ther, 68, pp.304~311 (2000)[DOI]
  8. de Bortoli N, "The pharmacokinetics of ilaprazole for gastroesophageal reflux treatment", Expert Opin Drug Metab Toxicol, 9, pp.1361~1369 (2013)[DOI]
  9. Du YQ, "Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study", J Dig Dis, 13, pp.113~119 (2012)[DOI]
  10. Fiocca R, "Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project", Hum Pathol, 41, pp.223~231 (2010)[DOI]
  11. Yerian L, "Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the Esohisto Project", Dig Dis Sci, 56, pp.2656~2665 (2011)[DOI]
  12. Weusten BL, "The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data", Gastroenterology, 107, pp.1741~1745 (1994)[DOI]
  13. Ward BW, "Ambulatory 24-hour esophageal pH monitoring. Technology searching for a clinical application", J Clin Gastroenterol, 8(Suppl 1), pp.59~67 (1986)[DOI]
  14. Tielemans MM, "Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study", BMC Gastroenterol, 13, pp.144~ (2013)[DOI]
  15. Tielemans MM, "Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument", Interact J Med Res, 1, pp.e7~ (2012)[DOI]
  16. Suzuki H, "Validation of the GerdQ questionnaire for the management of gastrooesophageal reflux disease in Japan", United European Gastroenterol J, 1, pp.175~183 (2013)[DOI]
  17. Quigley EM, "Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation", Chin J Dig Dis, 7, pp.186~190 (2006)[DOI]
  18. Savarino E, "Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients", J Gastroenterol, 47, pp.159~168 (2012)[DOI]
  19. Long JD, "Nonerosive reflux disease: a pathophysiologic perspective", Curr Gastroenterol Rep, 10, pp.200~207 (2008)[DOI]
  20. Stolte M, "Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus", Scand J Gastroenterol, 35, pp.1125~1130 (2000)[DOI]
  21. Vieth M, "What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa?", Dig Dis, 22, pp.196~201 (2004)[DOI]
  22. Kandulski A, "Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn", Aliment Pharmacol Ther, 38, pp.643~651 (2013)[DOI]
  23. Funch-Jensen P, "Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings", Scand J Gastroenterol, 21, pp.65~69 (1986)
  24. Kiesslich R, "Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy", Dig Dis, 22, pp.221~227 (2004)[DOI]
  25. Farre R, "Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus", Gut, 59, pp.164~169 (2010)[DOI]
  26. Caviglia R, "Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure", Am J Gastroenterol, 100, pp.543~548 (2005)[DOI]
  27. Isomoto H, "Immune and inflammatory responses in GERD and lansoprazole", J Clin Biochem Nutr, 41, pp.84~91 (2007)[DOI]
  28. Isomoto H, "Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease", Am J Gastroenterol, 99, pp.589~597 (2004)[DOI]
  29. Monkemuller K, "Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease", Digestion, 79, pp.186~195 (2009)[DOI]
  30. Shieh KR, "Evidence for neurotrophic factors associating with TRPV1 gene expression in the inflamed human esophagus", Neurogastroenterol Motil, 22, pp.971~977 (2010)[DOI]
  31. Isomoto H, "Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis", Am J Gastroenterol, 98, pp.551~556 (2003)[DOI]
  32. Isomoto H, "Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux", Am J Gastroenterol, 99, pp.1063~1068 (2004)[DOI]
  33. Yoshida N, "Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease", Scand J Gastroenterol, 39, pp.816~822 (2004)[DOI]
  34. Noordzij JP, "Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study", Laryngoscope, 111, pp.2147~2151 (2001)[DOI]

관련 논문AI추천

A Multicenter, Randomized, Comparative Study to Determine the Appropriate Dose of Lansoprazole for Use in the Diagnostic Test for Gastroesophageal Reflux Disease권중구, 김은영, 박창근, 양창헌, 이시형, 장병익, 전성우, 조광범거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제3호The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study김재규, 김재준, 문정섭, 박수헌, 신운건, 이동호, 이상우, 이용찬, 이항락, 장재영, 홍수진, 황보영, Bangmao Wang, Fei Liu, Frederick Dy, Jianming Xu, Somchai Leelakusolvong, Yaozong Yuan, Zhanxiong Xue거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제6호The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical StudyDa Hyun Jung, Eun Hye Kim, Hyojin Park, Jae Jun Park, Jie-Hyun Kim, Jun Chul Park, Sang Kil Lee, Sung Kwan Shin, Yong Chan Lee, Young Hoon Youn거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제6호A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease이강녕, 전훈재, 최석채, Baik Gwang Ho, Choi Myung Gyu, Hong Su Jin, Jang Jae Young, Jang Jin Seok, Jeon Yong Cheol, Kim Eun Young, Kim Gwang Ha, Kim Hyun Soo, Kim Jie-Hyun, Kim Tae Oh, Lee Jun Kyu, Lee Oh Young, Lee Yong Chan, Park Kyung Sik, Park Su Hyun, Sung In-Kyung거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제2호A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori-Negative Primary Care Patients with Dyspepsia in JapanAkiko Shiotani, Hiroshi Imamura, Jiro Hata, Kazuhiko Inoue, Ken Haruma, Kensuke Gotoh, Noriaki Manabe, Tomoari Kamada, Yoshinori Fujimura거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제1호Symptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease김상우, 김진수, 문성진, 박재명, 백명기, 이인석, 임철현, 조유경, 최규용, 최명규거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제2호

이 간행물의 다른 논문 (11건)